Menu

Man Receives First In Vivo Gene-Editing Therapy

The 44-year-old patient has Hunter syndrome, which doctors hope to treat using zinc finger nucleases.

Nov 15, 2017
Kerry Grens

Zinc finger motifWIKIMEDIA, THOMAS SPLETTSTOESSERIn a first, a man has received a therapy aimed at editing the genes inside his body. The Associated Press reports that 44-year-old Brian Madeux, who has a genetic condition called Hunter syndrome, was treated with zinc finger nucleases (ZFNs) targeting a deficient gene in his liver on Monday (November 13) at a hospital in Oakland, California.

“This is the first time someone could have a new gene put into their liver,” Sangamo President and CEO Sandy Macrae told The Scientist in May. “It’s a privilege and a responsibility to do” these trials.

“It’s kind of humbling,” Madeux tells the Associated Press about being the first to receive such an in vivo gene-editing treatment. “I’m willing to take that risk. Hopefully it will help me and other people.”

See “First In Vivo Genome Editing to Be Tested in Clinical Trial

Hunter syndrome is a rare condition in which people lack an enzyme that breaks down complex polysaccharides. To correct it, ZFNs are directed to cut the gene for albumin in liver cells, where the functional copy of the enzyme’s gene is then incorporated. The therapy was developed by California-based Sangamo Therapeutics.

Compared to genome editing based on CRISPR-Cas9, “zinc finger nucleases are a little more cumbersome to develop,” Paula Cannon of the University of Southern California’s Keck School of Medicine told The Scientist in May. But they offer superior specificity, she said. Sangamo’s system “gives you very specific and highly effective zinc finger nucleases,” said Cannon, who was not involved in the trial. “They can target ZFNs to cut at any particular base.”

Sangamo is also looking to begin treating hemophilia B and Hurler syndrome using ZFNs.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.